neostigmine has been researched along with Ataxia in 5 studies
Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.
neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.
Ataxia: Impairment of the ability to perform smoothly coordinated voluntary movements. This condition may affect the limbs, trunk, eyes, pharynx, larynx, and other structures. Ataxia may result from impaired sensory or motor function. Sensory ataxia may result from posterior column injury or PERIPHERAL NERVE DISEASES. Motor ataxia may be associated with CEREBELLAR DISEASES; CEREBRAL CORTEX diseases; THALAMIC DISEASES; BASAL GANGLIA DISEASES; injury to the RED NUCLEUS; and other conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Neostigmine methylsulfate has a quaternary ammonium group, which prevents its penetration through the blood-brain barrier; hence its primary influence is believed to be due to its action on the peripheral nervous system." | 5.31 | A female with central anticholinergic syndrome responsive to neostigmine. ( Francia, A; Parisi, P, 2000) |
| "All treatments induced mild or moderate ataxia." | 2.77 | Efficacy of concurrent epidural administration of neostigmine and lidocaine for perineal analgesia in geldings. ( DeRossi, R; Maciel, FB; Módolo, TJ; Pagliosa, RC, 2012) |
| "Neostigmine methylsulfate has a quaternary ammonium group, which prevents its penetration through the blood-brain barrier; hence its primary influence is believed to be due to its action on the peripheral nervous system." | 1.31 | A female with central anticholinergic syndrome responsive to neostigmine. ( Francia, A; Parisi, P, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| DeRossi, R | 1 |
| Maciel, FB | 1 |
| Módolo, TJ | 1 |
| Pagliosa, RC | 1 |
| Shetisky, GM | 1 |
| Shuster, J | 1 |
| Dilts, SL | 1 |
| Parisi, P | 1 |
| Francia, A | 1 |
| Duvoisin, RC | 1 |
| Katz, R | 1 |
1 trial available for neostigmine and Ataxia
| Article | Year |
|---|---|
Efficacy of concurrent epidural administration of neostigmine and lidocaine for perineal analgesia in geldings.
Topics: Analgesia, Epidural; Anesthetics, Local; Animals; Ataxia; Blood Pressure; Body Temperature; Cholines | 2012 |
4 other studies available for neostigmine and Ataxia
| Article | Year |
|---|---|
Ataxia telangiectasia.
Topics: Adolescent; Adult; Ataxia; Curare; Edrophonium; Female; Humans; Male; Neostigmine | 1967 |
Berry CA: Effect of cholinergic drugs on passive avoidance in the mouse.
Topics: Animals; Ataxia; Atropine; Avoidance Learning; Galvanic Skin Response; Locomotion; Male; Mecamylamin | 1967 |
A female with central anticholinergic syndrome responsive to neostigmine.
Topics: Ataxia; Blood-Brain Barrier; Child, Preschool; Cholinesterase Inhibitors; Female; Hallucinations; Hu | 2000 |
Reversal of central anticholinergic syndrome in man by physostigmine.
Topics: Aged; Ataxia; Central Nervous System Diseases; Child; Cognition Disorders; Delirium; Female; Halluci | 1968 |